rs7359397 — SH2B1 SH2B1 C/T

Regulatory CpG-SNP downstream of SH2B1 that reduces gene expression via allele-specific methylation, impairing leptin and insulin signaling and increasing NAFLD severity and insulin resistance risk

See your personal result for SH2B1

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

SH2B1's Hidden Regulator — How a Downstream SNP Silences Leptin Signaling

While rs7498665 (SH2B1 Thr484Ala) alters the structure of the SH2B1 protein, rs7359397 acts at an earlier level — it controls how much SH2B1 protein the cell makes in the first place. Located approximately 500 base pairs downstream of SH2B1 on chromosome 16, this variant sits within a CpG dinucleotide11 CpG dinucleotide
A cytosine-guanine pair that is a common target for DNA methylation, which silences nearby genes when heavily methylated. The T allele creates an allele-specific methylation pattern that suppresses SH2B1 promoter activity22 suppresses SH2B1 promoter activity
When the downstream CpG region is hypermethylated, transcriptional repressors recognize the modified DNA and reduce SH2B1 mRNA output, meaning less adaptor protein available to amplify leptin and insulin receptor signals, reducing the cell's capacity to amplify both leptin and insulin receptor signals downstream of JAK2.

This variant is notably common in European populations — about 42% of Europeans carry the T allele — and has been linked specifically to NAFLD severity, insulin resistance, and differential responses to dietary interventions.

The Mechanism

SH2B1 functions as a master amplifier of JAK2 signaling. When leptin binds its receptor on hypothalamic neurons, JAK2 autophosphorylates and SH2B1 binds to phospho-JAK2 via its SH2 domain33 SH2 domain
Src Homology 2 domain — a protein module that binds to specific phosphorylated tyrosine residues on activated kinases, dramatically increasing JAK2's catalytic activity and extending the signal through STAT3 to downstream appetite-suppressing genes. Less SH2B1 protein (due to rs7359397-driven hypermethylation) means less JAK2 amplification, blunted STAT3 phosphorylation, and reduced satiety signaling.

The CpG-SNP mechanism adds an epigenetic layer not present in coding variants: the T allele's methylation effects are potentially modifiable by dietary factors that influence one-carbon metabolism and global methylation status. This also explains the gene-diet interaction documented in intervention studies — T allele carriers respond differently to dietary composition changes that affect methyl-donor availability and insulin signaling.

The SH2B1 locus on chr16p11.2 is a dense LD block encompassing several genes (APOBR, SULT1A1, SULT1A2, TUFM); rs7359397 may partially tag effects at APOBR44 APOBR
Apolipoprotein B receptor — involved in lipid uptake and metabolism, with its own associations with extreme obesity in fine-mapping studies. The primary phenotypic signal, however, is attributed to reduced SH2B1 expression.

The Evidence

The Mansego et al. 2015 CpG-SNP study55 Mansego et al. 2015 CpG-SNP study
Mansego et al. SH2B1 CpG-SNP is associated with body weight reduction in obese subjects following a dietary restriction program. Annals of Nutrition and Metabolism, 2015 was the first to identify rs7359397 as a functional CpG-SNP, demonstrating that it showed the strongest association among seven obesity-related variants with weight, BMI, and truncal fat mass reduction during a caloric restriction program. The allele-specific methylation data linked the T allele to altered SH2B1 expression.

Two targeted studies from the Spanish FLiO (Fatty Liver in Obesity) cohort established the NAFLD connection. The 2020 cross-sectional study66 2020 cross-sectional study
Perez-Diaz-Del-Campo et al. Association of the SH2B1 rs7359397 Gene Polymorphism with Steatosis Severity in Subjects with Obesity and Non-Alcoholic Fatty Liver Disease. Nutrients, 2020 genotyped 110 obese/overweight subjects and found T allele carriers had dramatically higher rates of advanced NAFLD (69.1% vs 44.4%, p=0.006), elevated HOMA-IR (p=0.001), higher fatty liver index (OR 2.91), and nearly eight-fold greater risk of progressing to non-alcoholic steatohepatitis (RRR 7.88). The 2021 intervention follow-up77 2021 intervention follow-up
Perez-Diaz-Del-Campo et al. Differential response to a 6-month energy-restricted treatment depending on SH2B1 rs7359397 variant in NAFLD subjects: FLiO Study. European Journal of Nutrition, 2021 found that, despite worse baseline status, T allele carriers achieved 44.3% greater liver fat reduction (p<0.001) on the energy-restricted intervention — suggesting higher dietary sensitivity as a double-edged trait.

The insulin resistance effects extend beyond liver disease. The MAGIC consortium meta-analysis88 MAGIC consortium meta-analysis
Fall et al. The role of obesity-related genetic loci in insulin sensitivity. Diabetic Medicine, 2012 of 37,037 participants confirmed the SH2B1 rs7359397 association with HOMA-IR (P=3.9×10⁻³). Separately, a 5,641-person young adult cohort99 5,641-person young adult cohort
Lange et al. Evidence for Association between SH2B1 Gene Variants and Glycated Hemoglobin in Nondiabetic European American Young Adults. Annals of Human Genetics, 2016 found significant association with HbA1c (P=9.8×10⁻⁴) largely independent of BMI, indicating a metabolic effect that operates at least partly outside the obesity pathway.

Practical Actions

Because rs7359397 acts through epigenetic regulation of SH2B1 expression, T allele carriers are particularly responsive to dietary interventions. The FLiO studies demonstrate that energy restriction produces substantially greater liver fat reduction in T allele carriers — a rare example of a genetic variant that identifies who will respond best to dietary treatment. Practically, this means T allele carriers should not assume their worse NAFLD baseline translates to worse outcomes: the data suggest the opposite under active intervention.

Liver monitoring is specifically actionable here: T allele carriers face an elevated baseline risk of NAFLD progression to NASH (RRR 7.88), and periodic liver enzyme and ultrasound monitoring can detect this progression early, when intervention is most effective.

Omega-3 fatty acid supplementation is specifically relevant for T allele carriers in NAFLD: the FLiO intervention showed T allele carriers increased omega-3 intake during the intervention and achieved superior lipidomic improvements. Higher fiber intake also tracked with better outcomes in T allele carriers.

Interactions

rs7359397 and rs7498665 are both in SH2B1 but affect the gene at different levels — rs7359397 reduces SH2B1 protein quantity (expression regulation) while rs7498665 reduces SH2B1 protein quality (structural impairment). Carriers of both T and G risk alleles simultaneously face compounded SH2B1 impairment: less protein that also functions less efficiently. The two variants are in partial but not complete LD on chr16p11.2, so they can be inherited independently and co-occur in the same individual.

SH2B1 sits upstream of LEPR (rs1137101) in the leptin signaling cascade: SH2B1 amplifies JAK2 after the leptin receptor activates it. Carrying T at rs7359397 (reduced SH2B1 expression) while also carrying a suboptimal LEPR variant compounds impairment at two sequential steps in leptin signaling.

Nutrient Interactions

dietary fiber altered_metabolism
omega-3 fatty acids altered_metabolism

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal SH2B1 Expression Normal

Ancestral C/C genotype — full SH2B1 expression and leptin signaling

You carry two copies of the C allele at rs7359397. About 51% of people globally share this genotype; it is more common in East Asian (about 76%) and African (about 86%) populations. The C/C genotype maintains normal methylation levels at the downstream CpG region, preserving full SH2B1 transcription. Your hypothalamic neurons produce normal levels of this leptin signal amplifier, supporting efficient JAK2 activation and downstream appetite regulation.

CT Partial SH2B1 Suppression Intermediate

One T allele — moderately reduced SH2B1 expression and insulin sensitivity

The heterozygous state means approximately half of rs7359397 alleles carry the T allele's methylation mark. CpG methylation is cis-acting, so the T allele silences expression from that chromosome while the C allele chromosome maintains normal transcription. Overall SH2B1 protein output is approximately intermediate — reduced but not as severely as in TT homozygotes.

The NAFLD/NASH risk associated with this locus (OR 4.15 for the full T allele group in the FLiO cohort) is driven by TT homozygotes and T-allele carriers collectively; CT heterozygotes face intermediate risk. The strong dietary response documented for T allele carriers also applies to CT individuals.

TT Reduced SH2B1 Expression Reduced

Two T alleles — substantially impaired SH2B1 expression and high NAFLD risk

The TT genotype produces the maximum allele-specific methylation at the SH2B1 downstream CpG site. With both alleles methylated, SH2B1 mRNA levels are substantially reduced, and the resulting protein deficit impairs JAK2 amplification capacity across all cells expressing this gene.

In the liver, reduced SH2B1 signaling compromises insulin receptor transduction, impairing hepatic insulin sensitivity and promoting lipid accumulation — the first step in NAFLD. The 7.88-fold elevated NASH risk observed in T allele carriers is clinically significant: NASH (non-alcoholic steatohepatitis) involves active liver inflammation and fibrosis that can progress to cirrhosis.

The differential dietary response observed — T allele carriers achieving 44.3% greater liver fat reduction under energy restriction — suggests that SH2B1 expression is partially inducible by the metabolic environment. Caloric restriction and lower insulin levels may relieve epigenetic silencing or upregulate SH2B1 through compensatory pathways, explaining the paradoxically superior intervention response despite worse baseline.

The HbA1c association (P=9.8×10⁻⁴, largely BMI-independent) indicates metabolic effects on glucose control that operate independently of obesity status — lean TT carriers should not assume they are protected from insulin resistance complications.